PD1 inhibitors, also known as programmed death-1 inhibitors, are a class of pharmaceutical drugs used in cancer treatment. These inhibitors target the PD-1 receptor found on T cells, which plays a crucial role in regulating immune responses. By blocking the PD-1 receptor, PD1 inhibitors help to restore and enhance the body's natural immune response against cancer cells. These inhibitors have demonstrated significant efficacy in various disease indications, including advanced or metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, Hodgkin lymphoma, and microsatellite instability-high or mismatch repair deficient tumors. According to WHO, melanoma is the most aggressive form of skin cancer, with over 132,000 new cases diagnosed each year in Europe. In the USA, non-small cell lung cancer accounts for about 85% of all lung cancer cases, with approximately 228,000 new cases reported annually, and it remains the leading cause of cancer-related deaths. Renal cell carcinoma affects more than 100,000 individuals globally, with Europe accounting for a significant portion of these cases. Urothelial carcinoma is the second most common bladder cancer worldwide, with an estimated 550,000 new cases each year. Head and neck squamous cell carcinoma are responsible for approximately 890,000 cases globally, and around 90% of these cases are linked to tobacco and alcohol use. Hodgkin lymphoma is a rare cancer, with an estimated 90,000 new cases reported globally each year. Additionally, microsatellite instability-high or mismatch repair deficient tumors are found in a variety of cancer types, such as colorectal, endometrial, and gastric cancers.
The growth drivers of the PD1 inhibitors market include increasing awareness and understanding of immunotherapy, the proven efficacy of PD1 inhibitors in improving patient outcomes, a growing demand for advanced cancer treatments, and ongoing collaborations between pharmaceutical companies and research institutions. Companies such as Nippon Kayaku, Roche, UCB, PDl, Pfizer, Roche, BMS, and Bayer. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Otsuka is currently conducting a clinical trial of the drug SGI-110 for the treatment of leukemia.
Key Developments
- In June 2023, Merck got preregistration for Keytruda in biliary cancer (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy, Inoperable/Unresectable) in the USA
- In June 2023, the FDA assigned a PDUFA action date of February 7/02/2024 for pembrolizumab for Biliary cancer.
Approved PD1 Inhibitor Molecules
- Keytruda (pembrolizumab)
- Opdivo (nivolumab)
- Baizean (tislelizumab)
- AiRuiKa (camrelizumab)
- Tuoyi (toripalimab)
- Tyvyt (sintilimab)
- Libtayo (cemiplimab)
- Kaitanni (cadonilimab)
- Jemperli (dostarlimab-gxly)
- Spartalizumab (PDR001)
- Anniko (penpulimab)
- Hansizhuang (serplulimab)
- Zynyz (retifanlimab-dlwr)
- Puyouheng (pucotenlimab)
- Aibining (geptanolimab)
- Forteca (prolgolimab)
- Enshuxing (enlonstobart)
PD1 Inhibitor Pipeline Molecules
- Zimberelimab (AB122)
- Balstilimab (AGEN2034)
- Ezabenlimab (BI 754091)
- Ivonescimab (AK112)
- Budigalimab (ABBV-181)
- Cetrelimab (JNJ-63723283)
- Sasanlimab (PF-06801591)
- Pidilizumab (CT-011)
- Tobemstomig (RG6139)
- Volrustomig (MEDI5752)
- Rulonilimab (F520)
- Vudalimab (XmAb717)
- Finotonlimab (SCT-I10A)
- Nivolumab subcutaneous (BMS-986298)
- Reozalimab (IBI318)
- Tebotelimab (MGD013)
- Zeluvalimab (AMG 404)
- AM0001
- QL1604
- Nofazinlimab (CS1003)
- BZD1901
- T3011
- Rilvegostomig (AZD2936)
- 609A
- HX-009
- MEDI0680
- Sym021
- Lorigerlimab (MGD019)
- BAT1308
- IBI321
- ONO-4685
- SI-B003
- Izuralimab (XmAb23104)
- Pimivalimab (JTX-4014)
- AMP-224
- AZD7789
- BAT1306
- BRL-201
Clinical Activity and Development of PD1 Inhibitor
In the PD1 Inhibitor space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,
- In May 2023, BMS presented Pharmacodynamics data from a phase II trial of Opdivo in Small cell lung cancer at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- In June 2023, Merck presented efficacy and adverse events data from the phase III Keynote-716 trial of Keytruda in Malignant melanoma at the American Society of Clinical Oncology (ASCO-2023)
|
Product Name |
Total Studies |
|
Zimberelimab (AB122) |
48 |
|
Balstilimab (AGEN2034) |
28 |
|
Ezabenlimab (BI 754091) |
28 |
|
Ivonescimab (AK112) |
21 |
|
Budigalimab (ABBV-181) |
19 |
|
Cetrelimab (JNJ-63723283) |
17 |
|
Sasanlimab (PF-06801591) |
16 |
|
Pidilizumab (CT-011) |
15 |
|
Tobemstomig (RG6139) |
10 |
|
Volrustomig (MEDI5752) |
10 |
|
Rulonilimab (F520) |
8 |
|
Vudalimab (XmAb717) |
8 |
|
Finotonlimab (SCT-I10A) |
7 |
|
Nivolumab subcutaneous (BMS-986298) |
7 |
Target Indication Analysis of PD1 Inhibitor
PD-1 inhibitors, such as pembrolizumab and nivolumab, have shown promising results as targeted therapies for a range of indications. These include advanced or metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, Hodgkin lymphoma, and microsatellite instability-high or mismatch repair deficient tumors. PD-1 inhibitors work by blocking the PD-1 receptor on T cells, which prevents tumor cells from evading the immune response. This leads to enhanced immune activity against cancer cells, resulting in improved overall survival, progression-free survival, and durable responses in some patients. Ongoing research aims to expand the application of PD-1 inhibitors to other malignancies and optimize their use in combination with other therapies.
PD1 Inhibitor Market Regional Analysis
PD1 Inhibitors Market
The global PD1 Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US regional market analysis of PD1 Inhibitor reveals a robust and expanding landscape. The overall US regional market analysis of PD1 inhibitors in the pharmaceutical industry indicates a significant growth trajectory. With a robust healthcare infrastructure and a high prevalence of cancers such as melanoma, lung cancer, and urothelial carcinoma, the demand for PD1 inhibitors is substantial. Additionally, the presence of key market players, extensive research and development activities, and regulatory support contribute to the market's growth in the US. The market is primarily driven by factors such as increasing awareness about immunotherapy, the efficacy of PD1 inhibitors in enhancing patient outcomes, and a rising patient pool in need of advanced cancer treatments. Moreover, collaborations between pharmaceutical companies and research institutions further fuel the growth of the PD1 inhibitors market in the US. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for PD1 Inhibitors. These countries are increasingly adopting PD1 Inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the PD1 Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the PD1 Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
PD1 Inhibitor drugs are used in the management of advanced or metastatic melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell carcinoma, Hodgkin lymphoma, and microsatellite instability-high or mismatch repair deficient tumors.
Growth drivers of the PD1 Inhibitor market include technological advancements in PD1 Inhibitor sequencing and analysis methods, which have led to improved accuracy, speed, and cost-effectiveness of genetic testing. The declining costs of PD1 Inhibitor sequencing have made it more accessible, leading to increased adoption and utilization across various applications.
The major players in this space are Nippon Kayaku, Roche, UCB, PDl, Pfizer, Roche, BMS, and Bayer.
One of the key restraints of the PD-1 inhibitors market is the high cost of these therapies, which limits their accessibility and affordability for many patients. Additionally, the emergence of alternative immunotherapies and potential side effects associated with PD-1 inhibitors pose challenges to their widespread adoption and acceptance in the market.
- Nippon Kayaku
- Roche
- UCB
- PDl
- Pfizer
- Roche
- BMS
- Bayer
- Servier
- Vion
- SymBio Pharma
- Vivacitas
- Denovo
- EMD Serono
- Eli Lilly
- Imunon
- UroGen
- metronidazole
- Arrowhead
- Spectrum Pharma
- UroGen
- Daiichi Sankyo
- CTI BioPharma
- Cellectar
- Meabco
- Regulon
- Delcath
- Teva
- AstraZeneca